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Gene therapy for lung inflammatory diseases: not so far away?
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Abstract
promising results. [1] [2] [3] The advances made in these areas have prompted interest in the role The lung is a readily accessible target organ for gene therapy. To date, thera-of gene therapy as a means of positively influencing more complex pulmonary disorders peutic gene delivery has largely focused on introducing functional, corrective genes such as inflammatory lung diseases which might appear at first sight to be less amenable to in lung diseases arising from single gene defects such as cystic fibrosis. More re-genetic intervention. We shall confine our discussion to the potential application of gene cently interest has centred on gene therapy as a potential therapeutic tool in mod-therapy in inflammatory lung diseases (as an example of complex disease processes in the ulating complex pathological processes such as pulmonary inflammation. Genetic lung); however, it should be noted that farreaching and promising advances have been modification of critical components of the inflammatory process may be beneficial -made in applying gene therapy to, for example, lung tumours and HIV infection. for example, overexpressing anti-elastase genes may circumvent elastase mediated lung damage in emphysema. With the development of improved viral and liposome Scientific basis vectors and the evolution of effective ad-       juvant immunosuppression to obviate host  ? immune responses -for example, using To date over 100 clinical trials of gene therapy selective cytokines and blockers of T cell for cancer have been conducted and reported, surface activation -the potential exists to as well as 12 trials assessing gene therapy for target therapeutic doses of transgene to HIV and a further 21 for single gene defects deficient or dysregulated cells. Further-(mostly cystic fibrosis and 1 AT deficiency). more, increased understanding of tissue-However, as far as we are aware, no trials have specific promoter regions and of mech-assessed gene therapy for inflammatory lung anisms controlling regulation of gene diseases such as chronic obstructive pulmonary expression offer the potential for close con-disease (COPD), adult respiratory distress syntrol of therapeutic gene expression within drome (ARDS), and asthma. the lung.
Continuing refinements in these
The prevailing hypothesis is that inflamtechnologies will provide new therapeutic matory conditions such as COPD and ARDS strategies in inflammatory lung disease.
arise from an imbalance between potentially Further attempts to reduce host inflammatory responses and to enhance cell specificity and nuclear targeting are the focus of considerable research, and removal of the major hurdles toward effective, repeated gene therapy are keenly anticipated.
Therapeutic potential
The process of pulmonary inflammation is initiated by the stimulation of sequential migration of inflammatory cells from the circulation into the lung. Many pro-inflammatory molecules are potential targets for gene therapy. The influx of inflammatory cells could be prevented by counteracting the effects of selected cytokines and chemokines. For example, in situations where the "early" cytokines IL-1 and tumour necrosis factor (TNF) have been associated with adverse effects (such as in sepsis), overexpression of IL-1 receptor antagonist and soluble TNF receptor might be beneficial. Chemokines such as IL-8, responsible for the influx of neutrophils in ARDS, could be targeted using specific antisense DNA. Adhesion molecules present on inflammatory 
syndrome (ARDS) is characterised by both a local and systemic inflammation and is

Alternatively, overexpression of anti-intriggered by a variety of stimuli, including bacterial endotoxin. Human neutrophil elastase (HNE, Ν) is one enzyme released by the activated neutrophil which is believed to be
flammatory cytokines such as IL-10 could be involved in the pathology by destroying both the interstitium and the endothelium.
beneficial in the resolution of inflammation.
Protection against HNE could be provided by gene therapy using, for example, adenovirus
Indeed, recent in vivo work in rodents has monary inflammation by reducing both eosinophilia and neutrophilia, presumably, in the latter, through the promotion of apoptosis.
11
Intervention by modulating intracellular factors inflammation when administered in vivo, are in general poor gene transducers compared can also be envisaged. For example, the nuclear factor NF-B, which is known to be upwith adenoviruses. The latter have the opposite characteristics in that gene transduction is regulated during inflammation and involved in transcription of many inflammatory molecules efficient (by virtue of mechanisms avoiding lysosomal degradation and promoting transfer (for example, IL-1, IL-6, IL-8, VCAM-1), has recently been targeted by the overexpression of to the nucleus) but significant inflammation and a specific immune response are induced in its inhibitor I B . However, the relative lack of specificity of such nuclear factors must be vivo.
Addition of specific peptides (growth factors, carefully considered and may ultimately limit their clinical application. hormones, receptor ligands, or monoclonal antibodies) to liposome formulations can conFor the approaches discussed to be successful in obviating lung inflammation, careful planfer cell-specific targeting. 5 Furthermore, the poor transducing capability of liposomes can ning of the timing and duration of gene therapy will be vital. It will therefore be necessary to be addressed by increasing nuclear tropism using nuclear localisation signals. Reduction introduce mechanisms capable of "switching on" and "switching off" therapeutic genes. One of the pro-inflammatory and immunogenic properties of adenovirus vectors has been such mechanism attracting attention involves the use of inducible promoters for expression approached mainly by deleting some or all of the adenovirus genes 6 7 and by manipulating of selected genes. Examples of such promoters include the heat shock, tetracycline-and the host immune response. The latter can be steroid-responsive promoters. Furthermore, ameliorating the specificity and durability of expression, and in manipulating the host imthe use of lung-specific promoters such as surfactant protein C or Clara cell 10 kDa pro-mune response. At present liposomes and adenoviruses (or a combination of both) are the moters will ensure tissue-specific expression of therapeutic genes.
preferred vectors for use in the lungs, but if trials prove its safety then adeno-associated While there are clearly several attractions in aiming to attenuate the transmigration of virus could offer an attractive alternative by virtue of its selective integration site in human inflammatory cells into tissues, a more effective and possibly safer strategy may be to inactivate chromosome 19, conferring stable and sustainable expression. the potentially deleterious enzymes and reactive oxygen species liberated by effector cells in situ. Animal models of pulmonary inflamma-
